 |
Top 10 Genome Analysis startups in USA
Updated: May 01, 2024 |
1
Funding: $2B
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
2
Funding: $1.1B
23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.
23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.
3
Funding: $1.1B
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
4
Funding: $925.9M
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
5
Funding: $901.8M
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
6
Funding: $890.7M
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
7
Funding: $603.3M
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
9
Funding: $497M
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
10
Funding: $472.6M
DNAnexus combines expertise in cloud computing and Bioinformatics to create a global network for genomic medicine.
DNAnexus combines expertise in cloud computing and Bioinformatics to create a global network for genomic medicine.
Ad
Advertise your startup
11
Funding: $403M
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
12
Funding: $340.5M
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
13
Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
14
Funding: $254M
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
15
Funding: $244.7M
Our services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Our expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.
Our services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Our expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.
16
Funding: $225.1M
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy.
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy.
17
Funding: $221.7M
Our pioneering, flexible diagnostic instrument and disposable cartridge system is designed for decentralised laboratory, point-of–care and other near-patient settings. It provides a fast, easy-to-use and accurate affordable solution to screening for the presence of STIs and HAIs, where rapid diagnosis is essential for effective treatment and control.
Our pioneering, flexible diagnostic instrument and disposable cartridge system is designed for decentralised laboratory, point-of–care and other near-patient settings. It provides a fast, easy-to-use and accurate affordable solution to screening for the presence of STIs and HAIs, where rapid diagnosis is essential for effective treatment and control.
18
Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
19
Funding: $112M
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.
20
Funding: $108M
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
21
Funding: $100.5M
Variantyx offers a comprehensive set of advanced genomic diagnostic products and services with a focus on whole genome sequencing.
Variantyx offers a comprehensive set of advanced genomic diagnostic products and services with a focus on whole genome sequencing.
22
Funding: $96.5M
Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease. We bring a pan-cancer orientation to the treatment of both solid tumors and hematologic cancers, and help make precision medicine a reality for patients by providing comprehensive genomic profiles to oncologists to help them match their patients to targeted therapies.
Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease. We bring a pan-cancer orientation to the treatment of both solid tumors and hematologic cancers, and help make precision medicine a reality for patients by providing comprehensive genomic profiles to oncologists to help them match their patients to targeted therapies.
23
Funding: $76.2M
Recent scientific breakthroughs are revolutionizing the way we think about DNA and health. Orig3n is on a mission to turn these discoveries into practical solutions and make them available to you.
Recent scientific breakthroughs are revolutionizing the way we think about DNA and health. Orig3n is on a mission to turn these discoveries into practical solutions and make them available to you.
24
Funding: $73M
OncoCyte focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
OncoCyte focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
25
Funding: $65.4M
Mendel.ai automates matching cancer patients to clinical trials through personal medical history and genetic analysis.
Mendel.ai automates matching cancer patients to clinical trials through personal medical history and genetic analysis.
26
Funding: $61.4M
Veritas Genetics is the first company in medical history to offer individuals the opportunity to easily and affordably unlock the secrets of their entire genome. To know what truly, scientifically makes us tick, and to be able to put this knowledge to work each and every day.
Veritas Genetics is the first company in medical history to offer individuals the opportunity to easily and affordably unlock the secrets of their entire genome. To know what truly, scientifically makes us tick, and to be able to put this knowledge to work each and every day.
27
Funding: $55M
Replay is a genome writing company reprogramming biology by writing and delivering big DNA.
Replay is a genome writing company reprogramming biology by writing and delivering big DNA.
28
Funding: $29M
We are past Human Genome Project Scientists that are developing the next generation of diagnostics and disease monitoring tests for the 95% of diseases that cannot be diagnosed by DNA. We are on a war-path to advance drug development and clinical diagnostics through our unique RNA tests.
We are past Human Genome Project Scientists that are developing the next generation of diagnostics and disease monitoring tests for the 95% of diseases that cannot be diagnosed by DNA. We are on a war-path to advance drug development and clinical diagnostics through our unique RNA tests.
29
Funding: $23.8M
Massive Bio brings cancer genomics to the masses, to improve quality of care and minimize costs.
Massive Bio brings cancer genomics to the masses, to improve quality of care and minimize costs.
30
Funding: $17.5M
Nucleus combines genetic and non-genetic information and calculates the absolute risk scores for people for disease.
Nucleus combines genetic and non-genetic information and calculates the absolute risk scores for people for disease.
31
Funding: $16.5M
Genomic Prediction provides advanced genomic tests which improve IVF health outcomes.
Genomic Prediction provides advanced genomic tests which improve IVF health outcomes.
32
Your unique DNA profile can give you a lot of information about your health— but many consumers are left wondering what to do with that information. That’s where we come in. At Toolbox Genomics, our mission is to give you practical and actionable food & lifestyle recommendations based on your DNA.
33
Funding: $14.4M
20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer.
20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer.
34
TDx is a molecular diagnostic and precision medicine company focused on developing clinically useful lab tests that guide treatment decisions for better outcomes initially in oncology.
35
Funding: $11.4M
Cambrian Genomics makes the first hardware/systems for laser printing DNA. Researchers in academia & industry order or clone >$1b/year of DNA. CGI delivers high quality sequence verified DNA to buyers in this existing/growing worldwide market.
Cambrian Genomics makes the first hardware/systems for laser printing DNA. Researchers in academia & industry order or clone >$1b/year of DNA. CGI delivers high quality sequence verified DNA to buyers in this existing/growing worldwide market.
36
Funding: $10.6M
The world's First and Only Personalization Platform for Health and Wellness Products and Services Tailored to Your DNA and Lifestyle.
The world's First and Only Personalization Platform for Health and Wellness Products and Services Tailored to Your DNA and Lifestyle.
37
Funding: $10.3M
Next-generation sequencing and other high-throughput genomic measurement technologies are providing us with unprecedented visibility into the origins of health and disease. Understanding these datasets has the potential to create a paradigm shift in how we develop drugs, diagnose disease, prevent ailments, and treat patients, especially in complex cases such as cancer.
Next-generation sequencing and other high-throughput genomic measurement technologies are providing us with unprecedented visibility into the origins of health and disease. Understanding these datasets has the potential to create a paradigm shift in how we develop drugs, diagnose disease, prevent ailments, and treat patients, especially in complex cases such as cancer.
38
Funding: $8M
SelfDecode is a precision health software that is helping individuals take control of their health with personalized gene-based recommendations, while also empowering businesses with the science and technology to create their own precision health solutions.
SelfDecode is a precision health software that is helping individuals take control of their health with personalized gene-based recommendations, while also empowering businesses with the science and technology to create their own precision health solutions.
39
Funding: $4.3M
Nebula Genomics leverages blockchain technology to eliminate middlemen and empower people to own their personal genomic data.
Nebula Genomics leverages blockchain technology to eliminate middlemen and empower people to own their personal genomic data.
41
Funding: $2,2M
LifeNome’s AI-Driven Genome analysing platform helps your customers make informed choices targeted to their unique needs.
LifeNome’s AI-Driven Genome analysing platform helps your customers make informed choices targeted to their unique needs.
42
Funding: $1.4M
The Biomeme device is a real-time PCR thermocycler that attaches to your iPhone and enables you to perform gold-standard DNA analysis. Using our lab-free sample prep, you isolate DNA from your environment, add it to a specific test cartridge and put it into the thermocycler. In less than an hour you can determine the presence or absence of that target in your sample.
The Biomeme device is a real-time PCR thermocycler that attaches to your iPhone and enables you to perform gold-standard DNA analysis. Using our lab-free sample prep, you isolate DNA from your environment, add it to a specific test cartridge and put it into the thermocycler. In less than an hour you can determine the presence or absence of that target in your sample.
43
Funding: $1.1M
Genome Profiling is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers based on our proprietary, genome-wide methylation profiling platform to revolutionize the way we treat, diagnose, and predict chronic and life-threatening diseases.
Genome Profiling is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers based on our proprietary, genome-wide methylation profiling platform to revolutionize the way we treat, diagnose, and predict chronic and life-threatening diseases.
44
Sure Genomics, a personal genomic testing company, provides you a solution to acquire your full DNA sequence from CLIA certified labs. Your completed DNA sequence is then stored on our secure HIPAA compliant SureVault. Sure Genomic’s intuitive and interactive platform, SureView, displays your DNA data from SureVault allowing you to examine reports about your genomic past, present, and future.
45
Dante Labs is a genetic testing and data analysis company specialized in Whole Genome Sequencing. Our mission is to make advanced genetics accessible to everyone.